NCT03083743

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection（Dulanermin for Injection）in the Treatment of Advanced Non-small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 417 (actual)
• Sponsor: Shanghai Gebaide Biotechnology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The trial is to evaluate the efficacy and safety of recombinant human Apo-2 ligand in treating patients with advanced retreated non-small cell lung cancer

Conditions

• Non-small-cell Lung Cancer (NSCLC) Stage IV

Interventions

Type	Name	Description
BIOLOGICAL	Recombinant human Apo-2 ligand for Injection	150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
BIOLOGICAL	Placebo	150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle

Timeline

• Start date: 2016-10-01
• Primary completion: 2017-10-01
• Completion: 2018-06-01
• First posted: 2017-03-20
• Last updated: 2017-03-20

Locations

1 site across 1 country: China